文献类型：期刊文献

中文题名：Janus激酶3在临床应用中的研究与进展

英文题名：Correlation and progress of Janus kinase 3 in clinical application

作者：姜盼盼[1];王显红[2];董昌宏[2];包燕霞[2];权金星[3]

第一作者：姜盼盼

机构：[1]宁夏医科大学,宁夏银川750004;[2]甘肃中医药大学,甘肃兰州730030;[3]甘肃省人民医院内分泌科,甘肃兰州730000

第一机构：宁夏医科大学,宁夏银川750004

年份：2022

卷号：32

期号：9

起止页码：60

中文期刊名：中国现代医学杂志

外文期刊名：China Journal of Modern Medicine

收录：CSTPCD;;北大核心:【北大核心2020】；

语种：中文

中文关键词：Janus激酶3;血液系统疾病;免疫性疾病;肿瘤;动脉粥样硬化

外文关键词：janus kinase 3;hemic and lymphatic diseases;immune system diseases;neoplasms;atherosclerosis

摘要：Janus激酶3(JAK3)属于与膜相关的细胞内非受体酪氨酸蛋白激酶家族中的一个成员,由细胞因子及生长因子发起的信号通过JAK/STAT途径介导。JAK3主要在造血细胞和免疫细胞中表达,参与细胞的增殖、分化、迁移、存活等过程。JAK3在血管细胞、癌细胞等某些非造血细胞中也存在表达。JAK3作为一种平滑肌细胞增殖和血管重塑的新型调节剂,可能与动脉粥样硬化形成密切相关。该文从JAK3的结构、信号通路、生物学功能及临床应用方面进行综述。
Janus kinase 3(JAK3)is a member of the membrane-associated intracellular non-receptor tyrosine protein kinase family.Signals initiated by cytokines and growth factors are mediated through the JAK/STAT pathway.It is mainly expressed in hematopoietic cells and immune cells,and participates in the processes of cell proliferation,differentiation,migration,and survival.JAK3 is also expressed in certain non-hematopoietic cells including vascular cells and cancer cells.Recent studies have found that JAK3,a novel regulator of smooth muscle cell(SMC)proliferation and vascular remodeling,may be closely related to atherosclerosis.This article reviews the structure,signaling pathways,biological functions and clinical applications of human JAK3.